The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder

Psychopharmacology Bulletin

Volumn 42, Issue 4, 2009, Pages 5-22

  Sheehan, David V ^a   Rozova, Anna ^b   Gossen, E Roderich ^c   Gibertini, Michael ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Department of Pharmacovigilance and Medical Information ^*  (United States)

^c Labopharm Inc   (Canada)

^d SYNEOS HEALTH   (United States)

Author keywords

Antidepressive agents; Behavioral symptoms; Major depressive disorder; Trazodone

Indexed keywords

CONTRAMID; PLACEBO; TRAZODONE; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; CONTROLLED RELEASE FORMULATION; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUICIDAL IDEATION; TRAZODONE; TREATMENT OUTCOME;

EID: 79952996433     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Saletu-Zyhlarz GM, Anderer P, Arnold O, et al. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. Neuropsychobio. 2003;48:194-208. (Pubitemid 37548227)
2. Feighner JP, Boyer WF. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacol (Berl). 1988;(95 Suppl):S50-S53.
3. Goodwin FK. Predictors of antidepressant response. Bull Menninger Clin. 1993;57:146-160. (Pubitemid 23148484)
4. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65:870-880.
5. Farabaugh A, Mischoulon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005;20:87-91. (Pubitemid 40354397)
6. Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007;190:344-349. (Pubitemid 46580685)
7. Saghafi R, Brown C, Butters MA, et al. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder. Int J Geriatr Psychiatry. 2007;22:1141-1146. (Pubitemid 350120664)
8. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165:342-351. (Pubitemid 351704490)
9. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;(60 Suppl 17):28-31. (Pubitemid 29386037)
10. Krystal AD. Psychiatric comorbidity: the case for treating insomnia. Sleep Med Clin. 2006;1:359-365.
11. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59:1052-1060. (Pubitemid 43849658)
12. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4:331-355.
13. Stahl SM. Antidepressants. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. New York: Cambridge University Press. 2008;511-666.
14. Nierenberg AA, Ostacher MJ, Huffman JC, et al. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med. 2008;50:428-436. (Pubitemid 351521617)
15. Reiner PB, Kamondi A. Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current. Neuroscience. 1994;59:579-588. (Pubitemid 24131513)
16. Lenaerts V, Moussa I, Dumoulin Y, et al. Cross-linked high amylose starch for controlled release of drugs: recent advances. J Control Release. 1998;53:225-234. (Pubitemid 28218705)
17. Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized double-blind, placebo-controlled study. Psychiatry (Edgemont). 2009;6:20-33.
18. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14:99-106. (Pubitemid 24120707)
19. Marcus SC, Hassan M, Olfson M. Antidepressant switching among adherent patients treated for depression. Psychiatr Serv. 2009;60:617-623.
20. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51:161-170.
21. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252-260.
22. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149:734-750.
23. Gonda X, Fountoulakis KN, Kaprinis G, et al. Prediction and prevention of suicide in patients with unipolar depression and anxiety. Ann Gen Psychiatry. 2007;6:23.
24. Bolton JM, Belik SL, Enns MW, et al. Exploring the correlates of suicide attempts among individuals with major depressive disorder: findings from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2008;69:1139-1149. (Pubitemid 352031598)
25. Jindal RD. Insomnia in patients with depression: some pathophysiological and treatment considerations. CNS Drugs. 2009;23:309-329.
26. Luparini MR, Garrone B, Pazzagli M, et al. A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1117-1127. (Pubitemid 40017628)
27. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14:536-546.
28. Ashton AK, Jamerson BD, Weinstein WL, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res. 2008;66:96-106. (Pubitemid 40798035)